Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
EU agrees on agriculture safeguards as fronts harden in Mercosur deal - 27 Strange Devices to Make Your Party Stick Out!
- 3Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- 4Gartex Texprocess India to showcase innovations across textile ecosystem
- 5The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Is Trump going to war with Venezuela?
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- How mountain terraces have helped Indigenous peoples live with climate uncertainty
- Vote in favor of your #1 Kind of Cap
- The Most Compelling Books of the 10 years
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- Cyclone Narelle turns Australian skies blood red in ‘apocalyptic’ scenes
